• JNX4022 is an orally active, small molecule partial agonist at the NMDA receptor-associated glycine site
  • Highly brain penetrant
  • Strong pre-clinical demonstration of potential to reduce dyskinesia in Parkinson’s disease
  • Preliminary demonstration of clinical efficacy in small number of people with Parkinson’s disease
  • Based upon re-purposing of FDA-approved drug
  • Strong patent position
  • Excellent safety and toxicology profile over more than two decades of clinical use in a non-Parkinson’s indication
  • Ready to commence clinical studies in Parkinson’s disease